Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2022 - 04 - 25 save search
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
Published: 2022-04-25 (Crawled : 15:00) - biospace.com/
XAIR | $1.28 -3.76% -3.91% 260K
|
Technology Services
|
| O: 0.86%
H: 19.86%
C: 11.06%
covid-19 air positive
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
Published: 2022-04-25 (Crawled : 14:20) - biospace.com/
NKTX | $7.86 0.9% 0.89% 1.1M
|
Health Technology
|
| O: 88.03%
H: 0.0%
C: 0.0%
positive
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
Published: 2022-04-25 (Crawled : 14:20) - biospace.com/
AMTI 4 | $0.263 -14.3% -1.14% 0
|
Health Technology
|
| O: 3.76%
H: 1.07%
C: -2.13%
amt-101 trial positive results molecular topline phase 2
Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -0.94%
H: 6.04%
C: 5.41%
children program positive results publication phase 3 phase 2
ABUNDANT VISIBLE GOLD PANNED NEAR HISTORICAL WORKINGS OF MINERAL MOUNTAIN’S NEWLY ACQUIRED KING OF THE WEST DEPOSIT 7858-ACRE LAND POSITION HOSTS 5 LARGE-SCALE GOLD TARGETS
Published: 2022-04-25 (Crawled : 13:20) - mineralmtn.com
MNRLF | $0.2978 -63.73% 2.5K
|
n/a
| Email alert
Add to watchlist
acquired
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
Published: 2022-04-25 (Crawled : 13:00) - biospace.com/
AYTU | $2.86 3.6% 4.3K
|
Health Technology
|
| O: -2.45%
H: 10.0%
C: 3.17%
biopharma preclinical technology positive pre-clinical
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Published: 2022-04-25 (Crawled : 12:00) - globenewswire.com
OCGN | News A | $1.44 -9.43% -10.42% 7.2M
|
Health Technology
|
| O: -1.25%
H: 6.33%
C: 4.64%
ocu400 trial positive
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-04-25 (Crawled : 06:00) - globenewswire.com
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: -8.39%
H: 1.73%
C: 0.48%
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 4.29%
H: 9.59%
C: 8.22%
treatment chmp positive
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.